Novo Nordisk A/S logo

Novo Nordisk A/S (NOVd)

Market Closed
- Market Cap
48.26 P/E Ratio
1.86% Div Yield
- Volume
0 Eps
Want to track NOVd and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NOVd is not paying dividends to its shareholders.
The last earnings report, released on May 06, 2026, missed the consensus estimates by -5.25%. On average, the company has fell short of earnings expectations by -4.856%, based on the last three reports.
Novo Nordisk A/S has completed 2 stock splits, with the recent split occurring on Sep 13, 2023.
The company's stock is traded on 11 different exchanges and in various currencies, with the primary listing on XETRA (EUR).

Novo Nordisk A/S (NOVd) FAQ

On which exchange is it traded?

Novo Nordisk A/S is listed on CBOE.

What is its stock symbol?

The ticker symbol is NOVd.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.86%.

What is its market cap?

As of today, no market cap data is available.

Has Novo Nordisk A/S ever had a stock split?

Novo Nordisk A/S had 2 splits and the recent split was on Sep 13, 2023.

Novo Nordisk A/S Profile

Biotechnology Industry
Healthcare Sector
Maziar Mike Doustdar CEO
CBOE Exchange
DK0062498333 ISIN
DK Country
77,406 Employees
27 Mar 2026 Last Dividend
13 Sep 2023 Last Split
- IPO Date

Overview

Novo Nordisk A/S is a globally recognized pharmaceutical company, established in 1923 and headquartered in Bagsvaerd, Denmark. The company, along with its subsidiaries, is deeply involved in the research, development, manufacture, and distribution of pharmaceutical products across various regions including Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. Novo Nordisk operates primarily in two business segments: Diabetes and Obesity Care, and Rare Disease. The company is committed to improving patient health by offering innovative solutions in diabetes care, weight management, and treatment for rare conditions. Additionally, Novo Nordisk advances in smart diabetes management solutions and collaborates with other pharmaceutical entities like Aspen Pharmaceuticals to bolster its production capabilities in insulin products.

Products and Services

  • Diabetes and Obesity Care:

    This segment includes a wide range of products for managing diabetes, obesity, cardiovascular issues, and exploring other emerging therapy areas. Novo Nordisk’s initiatives in this category aim at providing comprehensive care and treatment options to patients suffering from these chronic conditions.

  • Rare Disease:

    Focuses on delivering treatments for rare blood disorders, rare endocrine disorders, and hormone replacement therapies. By addressing these less common but significant healthcare challenges, Novo Nordisk strives to offer hope and better quality of life for individuals affected by rare diseases.

  • Insulin and Growth Hormone Delivery Devices:

    Novo Nordisk is a pioneer in developing and providing insulin pens, growth hormone pens, and injection needles. These devices are designed to make the self-administration of insulin and growth hormones easier, safer, and more convenient for patients.

  • Smart Solutions for Diabetes Management:

    Leveraging technology, Novo Nordisk offers smart insulin pens and Dose Check, an innovative insulin dose guidance application. These smart solutions are aimed at enhancing the control and management of diabetes by simplifying medication adherence and dose accuracy.

Contact Information

Address: Novo Allé 1
Phone: 45 44 44 88 88